MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
16.78
+0.05 (0.30%)
Mar 17, 2026, 3:38 PM EDT - Market open

MLTX Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
-41.97-30.32-22.32-23.01-
Research & Development
-202.86-112.77-31.8-42.05-
Other Operating Expenses
-244.83-143.09-54.12-65.06-
Total Operating Expenses
-489.67-286.18-108.25-130.120
Operating Income
-244.83-143.09-54.12-65.06-
Interest Expense
-7.25----
Other Non-Operating Income (Expense)
22.3722.1310.140.59-
Total Non-Operating Income (Expense)
15.1222.1310.140.59-
Pretax Income
-229.71-120.96-43.99-64.47-
Provision for Income Taxes
0.610.280.090.04-
Net Income
-227.32-118.94-36.01-64.51-4.54
Minority Interest in Earnings
-3-2.31-8.07--
Net Income to Common
-227.32-118.94-36.01-64.51-4.54
Shares Outstanding (Basic)
6463493811
Shares Outstanding (Diluted)
6463493811
Shares Change (YoY)
2.54%27.99%29.46%252.97%-
EPS (Basic)
-3.53-1.89-0.73-1.70-1.01
EPS (Diluted)
-3.53-1.89-0.73-1.70-1.01
Free Cash Flow
-196.04-117.11-43.06-55.91-0.61
Free Cash Flow Per Share
-3.04-1.86-0.88--0.06
EBITDA
-242.22-141.71-53.75-64.90
EBIT
-244.83-143.09-54.12-65.06-
Effective Tax Rate
-0.27%-0.23%-0.21%-0.06%-
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q